Skip to main content
Veterinary Medicines

Rabitec (--) - Oral suspension

Authorised
  • Rabies virus, strain SPBN GASGAS, Live

Product identification

Medicine name:
Rabitec (--) - Oral suspension
Active substance:
  • Rabies virus, strain SPBN GASGAS, Live
Target species:
  • Fox
  • Raccoon dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Rabies virus, strain SPBN GASGAS, Live
    Presentation_strength:10 ⁶·⁸ to 10⁸·¹ FFU Reference:Hse Index:0
Pharmaceutical form:
  • Oral suspension
Withdrawal period by route of administration:
  • Oral use
    • Fox
    • Raccoon dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07BD
Authorisation status:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Package description:
  • Packaging:Suspension: Blister (PVC-Alu); bait: matrix, Package_size:800 bait, Content:Suspension: 1.7 ml (one dose); bait: PE bag
  • Packaging:Suspension: Blister (PVC-Alu); bait: matrix, Package_size:800 bait, Content:Suspension: 1.7 ml (one dose); bait: PE sleeve
  • Packaging:Suspension: blister (PVC-Alu); bait: matrix, Package_size:800 bait, Content:Suspension: 1.7 ml (one dose); bait: PE bag

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • CEVA Santé Animale
Marketing authorisation date:
Manufacturing sites for batch release:
  • IDT Biologika GmbH
  • Ceva Tiergesundheit (Riems) GmbH
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

English (PDF)
Published on: 16/10/2024
Download
Bulgarian (PDF)
Published on: 16/10/2024
Croatian (PDF)
Published on: 16/10/2024
Czech (PDF)
Published on: 16/10/2024
Danish (PDF)
Published on: 16/10/2024
Dutch (PDF)
Published on: 16/10/2024
Estonian (PDF)
Published on: 16/10/2024
Finnish (PDF)
Published on: 16/10/2024
French (PDF)
Published on: 16/10/2024
German (PDF)
Published on: 16/10/2024
Greek (PDF)
Published on: 16/10/2024
Hungarian (PDF)
Published on: 16/10/2024
Icelandic (PDF)
Published on: 16/10/2024
Italian (PDF)
Published on: 16/10/2024
Latvian (PDF)
Published on: 16/10/2024
Lithuanian (PDF)
Published on: 16/10/2024
Maltese (PDF)
Published on: 16/10/2024
Norwegian (PDF)
Published on: 16/10/2024
Polish (PDF)
Published on: 16/10/2024
Portuguese (PDF)
Published on: 16/10/2024
Romanian (PDF)
Published on: 16/10/2024
Slovak (PDF)
Published on: 16/10/2024
Slovenian (PDF)
Published on: 16/10/2024
Spanish (PDF)
Published on: 16/10/2024
Swedish (PDF)
Published on: 16/10/2024

ema-puar-v4387-rabitec-vra0011-en.pdf

English (PDF)
Published on: 23/09/2024
Download

ema-puar-rabitec-v-4387-par-en.pdf

English (PDF)
Published on: 15/03/2023
Download

ema-puar-rabitec-v-4387-var-ii-002-en.pdf

English (PDF)
Published on: 15/03/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."